Treatment of severe aplastic anemia with sequential immunosuppression

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Severe aplastic anemia (SAA) is a life-threatening condition characterized by bone marrow failure.
• Treatment options for SAA include bone marrow transplantation and immunosuppressive therapy (IS).
• Identifying effective IS regimens is crucial for patients ineligible for transplantation.

Purpose of the Study:

• To evaluate the efficacy and outcomes of various immunosuppressive therapy (IS) regimens in patients with severe aplastic anemia (SAA).
• To determine the response rates, transfusion independence, and survival in SAA patients treated with IS.
• To assess the long-term outcomes of IS for SAA patients, particularly those without bone marrow transplant options.

Main Methods:

• Forty-two patients with SAA received one or more courses of IS, including high-dose bolus methylprednisolone, horse or rabbit antilymphocytic globulin, androgens, and haploidentical marrow infusions.
• Patients were monitored for hematologic reconstitution, transfusion requirements, and survival.
• Response rates and actuarial survival were calculated for different treatment courses and overall patient cohort.

Main Results:

• An overall response rate of 57% (24/42 patients) was observed following IS treatment.
• Responders achieved transfusion independence, with 17 patients off maintenance therapy.
• The actuarial 5-year survival rate was 60%, with a significant proportion of survivors followed long-term.

Conclusions:

• Immunosuppressive therapy (IS) is an effective treatment for over 50% of severe aplastic anemia (SAA) patients.
• IS provides a viable therapeutic option for SAA patients who cannot undergo bone marrow transplantation.
• Long-term transfusion independence and survival are achievable with appropriate IS regimens in SAA.